Proteus Digital Health
Proteus Digital Health developed Digital Medicines, a system using ingestible sensors to track medication adherence and capture physiological data.
Secondary Market Price
How Proteus Digital Health Measures Up
To help you manage your Proteus Digital Health equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series H
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Proteus Digital Health's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Proteus Digital Health Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Proteus Digital Health's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Proteus Digital Health, which ceased operations in 2020, was a company that developed and commercialized digital health products. Founded in 2001 by Andrew Thompson, George Savage, and Mark Zdeblick, the company pioneered a category of products it called Digital Medicines. These products involved pharmaceuticals with ingestible sensors that communicated when a medication was taken. This system worked in conjunction with wearable sensors that captured physiological data like heart rate and activity, and mobile applications that allowed patients and physicians to review the information. Over its history, the company raised a total of $517 million in funding and reached a market valuation of $1.6 billion in 2016.
As Proteus Digital Health is now defunct, there are no recent announcements or forward-looking developments for the company. Operations ceased in 2020, and it is no longer active in the market.
- Oracle
- Novartis
- Otsuka Pharmaceutical
- Medtronic
- Kaiser Permanente Ventures
- Co-Founder, Andrew Thompson
- Co-Founder, George Savage
- Co-Founder, Mark Zdeblick
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Proteus Digital Health worth joining?
Deciding whether to join a company like Proteus Digital Health requires evaluating its growth potential, leadership, and the value of its compensation package. Tools like Prospect can help you analyze the equity component by projecting its potential future value based on various market signals.
What should I do with my Proteus Digital Health stock?
The best strategy for your Proteus Digital Health stock depends on your personal financial goals, risk tolerance, and tax situation. Using a platform like Prospect can provide customized, multi-year exercise and sale strategies to help you maximize your returns.
Can you sell Proteus Digital Health stock?
As a private company, selling Proteus Digital Health stock is typically possible through secondary markets or during company-organized liquidity events like tender offers. Prospect offers tools to help you navigate these opportunities and determine which shares are the most tax-optimal to sell.
How can I find the value of my Proteus Digital Health stock?
The value of private stock is often determined by the company's latest 409A valuation, but you can also look at recent secondary market transactions for pricing data. To better understand its potential future worth, Prospect uses machine learning models to project a likely range of outcomes for your equity.
What is Proteus Digital Health's equity worth?
The precise worth of private equity like that from Proteus Digital Health fluctuates and is not publicly listed. You can get a data-driven estimate by using Prospect, which analyzes factors like funding rounds and market trends to forecast your equity's potential value.
What is Proteus Digital Health's stock ticker symbol?
As a private company, Proteus Digital Health is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned only when a company completes an Initial Public Offering (IPO).
Can I buy or sell Proteus Digital Health stock?
Selling private stock is possible through secondary markets or tender offers, while buying is typically restricted to accredited investors and subject to company approval. Platforms like Prospect provide tools and insights to help current employees make informed decisions about selling their existing shares.
What is the criteria to buy or invest in Proteus Digital Health stock?
To invest in a private company like Proteus Digital Health, you generally need to be an accredited investor, which is a status defined by specific income or net worth thresholds. These transactions typically occur on secondary markets and are subject to the company's right of first refusal.
